Pathological aspects of malignant and benign thymic disorders

Annals of Medicine

Volumn 31, Issue SUPPL. 2, 1999, Pages 5-14

  Müller Hermelink, Hans K ^a   Marx, Alexander ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Acetylcholine receptor; Autoimmunity; Pathogenesis; Thymoma classification; Thymus; WHO

Indexed keywords

AUTOANTIBODY; CHOLINERGIC RECEPTOR;

CANCER CLASSIFICATION; CANCER GRADING; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; EPITHELIUM TUMOR; HUMAN; HUMAN TISSUE; MYASTHENIA GRAVIS; PATHOLOGY; PRIORITY JOURNAL; PSEUDOSARCOMA; T LYMPHOCYTE; THYMOMA; THYMUS DISEASE; WORLD HEALTH ORGANIZATION;

CARCINOMA; HUMANS; MYASTHENIA GRAVIS; PROGNOSIS; THYMOMA; THYMUS GLAND; THYMUS NEOPLASMS; WORLD HEALTH ORGANIZATION;

EID: 0032730864     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (43)

1. Rosai J, Sobin LH. Histological typing of tumours of the thymus. In: World Health Organization, International Histological Classification of Tumours. Heidelberg, Germany: Springer; 1999: 1-65.
2. Bernatz PE, Harrison EG, Glagett OT. Thymoma. A clinicopathologic study. J Thorac Cardiovasc Surg 1961; 42: 424-44.
3. Lattes R. Thymoma and other tumors of the thymus. An analysis of 107 cases. Cancer 1962; 15: 1224-60.
4. Levine GD, Rosai J. Thymic hyperplasia and neoplasia. A review of current concepts. Hum Pathol 1978; 9: 495-515.
5. Lewis JE, Wick MR, Scheithauer BW, Bernatz PE, Taylor WF. Thymoma. A clinicopathologic review. Cancer 1987; 60: 2727-43.
6. Shimosato Y, Mukai K. Tumors of the mediastinum. In: Rosai J, Sobin LH, eds. Atlas of Tumor Pathology. 3rd edn. Washington, DC: Armed Forces Institute of Pathology; 1997: 93-115.
7. Marino M, Müller-Hermelink HK. Thymoma and thymic carcinoma. Relation of thymic epithelial cells to the cortical and medullary differentiation of thymus. Virchows Arch A Pathol Anat Histopathol 1985; 407: 119-49.
8. Kirchner T, Müller-Hermelink HK. New approaches to the diagnosis of thymic epithelial tumors. Prog Surg Pathol 1989; 10: 167-89.
9. Kirchner T, Schalke B, Buchwald J, Ritter M, Marx A, Müller-Hermelink HK. Well-differentiated thymic carcinoma. An organotypical low-grade carcinoma with relationship cortical thymoma. Am J Surg Pathol 1992; 16: 1153-69.
10. Quintanilla-Martinez L, Wilkins EW Jr, Ferry JA, Harris NL. Thymoma-morphologic subclassification correlates with invasiveness and immunohistologic features: a study of 122 cases. Hum Pathol 1993; 24: 958-69.
11. Pescarmona E, Rendina EA, Venuta F, Ricci C, Ruco LP, Baroni CD. The prognostic implication of thymoma histologic subtyping. A study of 80 consecutive cases. Am J Clin Pathol 1990; 93: 190-5.
12. Ho FCS, Fu KH, Lam SY, Chiu SW, Chan ACL, Müller-Hermelink HK. Evaluation of a histogenetic classification for thymic epithelial tumors. Histopathology 1994; 25: 21-9.
13. Kuo TT, Lo S-K. Thymoma: a study of the pathologic classification of 71 cases with evaluation of the Müller-Hermelink system. Hum Pathol 1993; 24: 766-71.
14. Pan CC, Wu HP, Yang CF, Chen WY-K, Chiang H. The clinicopathological correlation of epithelial subtyping in thymoma: a study of 112 consecutive cases. Hum Pathol 1994; 25: 893-9.
15. Quintanilla-Martinez L, Wilkins EW Jr, Choi N, Efird J, Hug E, Harris NL. Thymoma. Histologic subclassification is an independent prognostic factor. Cancer 1994; 74: 606-17.
16. Müller-Hermelink HK, Wilisch A, Schultz A, Marx A. Characterization of the human thymic microenvironment: lymphoepithelial interaction in normal thymus and thymoma. Arch Histol Cytol 1997; 60: 9-28.
17. Suster S, Moran CA. Primary thymic epithelial neoplasms showing combined features of thymoma and thymic carcinoma. A clinicopathological study of 22 cases. Am J Surg Pathol 1996; 20: 1469-80.
18. Suster S, Moran CA, Chan JK. Thymoma with pseudosarcomatous stroma: report of an unusual histologic variant of thymic epithelial neoplasm that may simulate carcinosarcoma. Am J Surg Pathol 1997; 21: 1316-23.
19. Yoneda S, Marx A, Heimann S, Shirakusa T, Kikochi M, Müller-Hermelink HK. Low-grade metaplastic carcinoma of the thymus. Histopathology 1999; 35: 19-30.
20. Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymoma with special reference to their clinical stages. Cancer 1981; 48: 2485-92.
21. Marx A, Müller-Hermelink HK. Thymoma and thymic carcinoma (letter). Am J Surg Pathol 1999; 23: 739-40.
22. Verley JM, Hollmann KH. Thymoma. A comparative study of clinical stages, histologic features and survival in 200 cases. Cancer 1985; 55: 1074-86.
23. Marx A, Wilisch A, Schultz A, Gattenlohner S, Nenninger R, Müller-Hermelink HK. Pathogenesis of myasthenia gravis. Virchows Arch 1997; 430: 355-64.
24. Marx A, Schultz A, Wilisch A, Helmreich M, Nenninger R, Müller-Hermelink HK. Paraneoplastic autoimmunity in thymus tumors. Dev Immunol 1998; 6: 129-40.
25. Robertson NP, Deans J, Compston DA. Myasthenia gravis: a population based epidemiological study in Cambridgeshire, England. J Neurol Neurosurg Psychiatry 1998; 65: 492-6.
26. Incidence of myasthenia gravis in the Emilia-Romagna region: a prospective multicenter study. Emilia-Romagna Study Group on Clinical Epidemiological Problems in Neurology. Neurology 1998; 51: 255-8.
27. Kirchner T, Hoppe F, Schalke B, Müller-Hermelink HK. Microenvironment of thymic myoid cells in myasthenia gravis. Virchows Arch B Cell Pathol Incl Mol Pathol 1988; 54: 295-302.
28. Schalke B, Mertens HG, Kirchner T, Wegener S, Müller-Hermelink HK. Long-term treatment with azathioprine abolishes thymic lymphoid follicular hyperplasia in myasthenia gravis. Lancet 1987: 2; 682.
29. Wekerle H, Ketelsen UP. Intrathymic pathogenesis and dual genetic control of myasthenia gravis. Lancet 1977; 1: 678-80.
30. Vincent. Aetiological factors in development of myasthenia gravis. Neuroimmunology 1994; 4: 355-71.
31. Onodera J, Nakamura S, Nagano I, Tobita M, Yoshioka M, Takeda A, et al. Upregulation of bc1-2 in the myasthenic thymus. Ann Neurol 1996; 39: 521-8.
32. Masunaga A, Arai T, Yoshitake T, Titoyama S, Sugawara I. Reduced expression of apoptosis-related antigens in thymuses from patients with myasthenia gravis. Immunol Lett 1994; 39: 169-72.
33. Moulian N, Bidault J, Trauffault F, Yamamoto AM, Levasseur P, Berrih-Aknin S. Thymocyte Fas expression is dysregulated in myasthenia gravis patients with antiacetylcholine receptor antibody. Blood 1997; 89: 3287-95.
34. Garchon HJ, Djabiri F, Viard JP, Gajdos P, Bach JF. Involvement of human muscle acetylcholine receptor alpha-subunit gene (CHRNA) in susceptibility to myasthenia gravis. Proc Natl Acad Sci U S A 1994; 91: 4668-72.
35. Wakkach A, Guyon T, Bruand C, Tzartos S, Cohen-Kaminsky S, Berrih-Aknin S. Expression of acetylcholine receptor genes in human thymic epithelial cells: implications for myasthenia gravis. J Immunol 1997; 157: 3752-60.
36. Wilisch A, Gutsche S, Hoffacker V, Schultz A, Tzartos S, Nix W, et al. Association of AChR a subunit gene expression in mixed thymoma with myasthenia gravis. Neurology 1999; 52: 1460-6.
37. Nenninger R, Schultz A, Hoffacker V, Helmreich M, Wilisch A, Vandekerckhove B, et al. Abnormal thymocyte development and generation of autoreactive T cells in mixed and cortical thymomas. Lab Invest 1998; 78: 743-53.
38. Kirchner T, Tzartos S, Hoppe F, Schalke B, Wekerle H, Müller-Hermelink HK. Pathogenesis of myasthenia gravis. Acetylcholine receptor-related antigenic determinants in tumor-free thymuses and thymic epithelial tumors. Am J Pathol 1988; 130: 268-80.
39. Fukui Y, Ishimoto T, Utsuyama M, Gyotoku T, Koga T, Nakao K, et al. Positive and negative CD4+ thymocyte selection by a single MHC class II/peptide ligand affected by its expression level in the thymus. Immunity 1997; 6: 401-10.
40. Sommer N, Willcox N, Harcourt GC, Newsom-Davis J. Myasthenic thymus and thymoma are selectively enriched in acetylcholine receptor-reactive T cells. Ann Neurol 1990; 28: 312-9.
41. Huang D, Liu L, Noren K, Xia SQ, Trifunovic J, Pirskanen R, et al. Genetic association of Ctla-4 to myasthenia gravis with thymoma. J Neuroimmunol 1998; 88: 192-8.
42. Meager A, Vincent A, Newsom-Davis J, Willcox N. Spontaneous neutralising antibodies to interferon-alpha and interleukin-12 in thymoma-associated autoimmune disease. Lancet 1997, 350: 1596-7.
43. Marie J, Wakkach A, Condry A, Chastre E, Berrih-Aknio S, Gespach C. Funtional expression of receptors for calcitonin gene-related peptide, calcitonin, and vasoactive intestinal peptide in the human thymus and thymoma from myasthenia gravis patients. J Immunol 1999; 162: 2103-12.